These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 34864305)

  • 1. Validation of biomarkers in Huntington disease to support the development of disease-modifying therapies: A systematic review and critical appraisal scheme.
    Tang H; van Eimeren T; Sampaio C; Mestre TA
    Parkinsonism Relat Disord; 2021 Dec; 93():89-96. PubMed ID: 34864305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study.
    Lipsmeier F; Simillion C; Bamdadian A; Tortelli R; Byrne LM; Zhang YP; Wolf D; Smith AV; Czech C; Gossens C; Weydt P; Schobel SA; Rodrigues FB; Wild EJ; Lindemann M
    J Med Internet Res; 2022 Jun; 24(6):e32997. PubMed ID: 35763342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?
    Niemelä V; Landtblom AM; Blennow K; Sundblom J
    PLoS One; 2017; 12(2):e0172762. PubMed ID: 28241046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease.
    Sturrock A; Laule C; Decolongon J; Dar Santos R; Coleman AJ; Creighton S; Bechtel N; Reilmann R; Hayden MR; Tabrizi SJ; Mackay AL; Leavitt BR
    Neurology; 2010 Nov; 75(19):1702-10. PubMed ID: 21060093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the Risk of Huntington's Disease with Multiple Longitudinal Biomarkers.
    Li F; Li K; Li C; Luo S;
    J Huntingtons Dis; 2019; 8(3):323-332. PubMed ID: 31256145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease.
    Boileau NR; Stout JC; Paulsen JS; Cella D; McCormack MK; Nance MA; Frank S; Lai JS; Carlozzi NE
    J Huntingtons Dis; 2017; 6(3):201-215. PubMed ID: 28968239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.
    Carlozzi NE; Goodnight S; Kratz AL; Stout JC; McCormack MK; Paulsen JS; Boileau NR; Cella D; Ready RE
    J Huntingtons Dis; 2019; 8(4):467-482. PubMed ID: 31424415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
    Tabrizi SJ; Langbehn DR; Leavitt BR; Roos RA; Durr A; Craufurd D; Kennard C; Hicks SL; Fox NC; Scahill RI; Borowsky B; Tobin AJ; Rosas HD; Johnson H; Reilmann R; Landwehrmeyer B; Stout JC;
    Lancet Neurol; 2009 Sep; 8(9):791-801. PubMed ID: 19646924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.
    Tabrizi SJ; Reilmann R; Roos RA; Durr A; Leavitt B; Owen G; Jones R; Johnson H; Craufurd D; Hicks SL; Kennard C; Landwehrmeyer B; Stout JC; Borowsky B; Scahill RI; Frost C; Langbehn DR;
    Lancet Neurol; 2012 Jan; 11(1):42-53. PubMed ID: 22137354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding speech and swallowing difficulties in individuals with Huntington disease: Validation of the HDQLIFE Speech Difficulties and Swallowing Difficulties Item Banks.
    Carlozzi NE; Boileau NR; Roberts A; Dayalu P; Hanifan DL; Miner JA; Claassen D; Provost EM
    Qual Life Res; 2021 Jan; 30(1):251-265. PubMed ID: 32839864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?
    Carlozzi NE; Schilling S; Kratz AL; Paulsen JS; Frank S; Stout JC
    Qual Life Res; 2018 Oct; 27(10):2541-2555. PubMed ID: 29909483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 8OHdG is not a biomarker for Huntington disease state or progression.
    Borowsky B; Warner J; Leavitt BR; Tabrizi SJ; Roos RA; Durr A; Becker C; Sampaio C; Tobin AJ; Schulman H
    Neurology; 2013 May; 80(21):1934-41. PubMed ID: 23616162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biofluid Biomarkers in Huntington's Disease.
    Rodrigues FB; Byrne LM; Wild EJ
    Methods Mol Biol; 2018; 1780():329-396. PubMed ID: 29856027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging.
    Russell DS; Jennings DL; Barret O; Tamagnan GD; Carroll VM; Caillé F; Alagille D; Morley TJ; Papin C; Seibyl JP; Marek KL
    Neurology; 2016 Feb; 86(8):748-54. PubMed ID: 26802091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker development for Huntington's disease.
    Andre R; Scahill RI; Haider S; Tabrizi SJ
    Drug Discov Today; 2014 Jul; 19(7):972-9. PubMed ID: 24632006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease.
    Russell DS; Barret O; Jennings DL; Friedman JH; Tamagnan GD; Thomae D; Alagille D; Morley TJ; Papin C; Papapetropoulos S; Waterhouse RN; Seibyl JP; Marek KL
    JAMA Neurol; 2014 Dec; 71(12):1520-8. PubMed ID: 25322077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Motor outcome measures in Huntington disease clinical trials.
    Reilmann R; Schubert R
    Handb Clin Neurol; 2017; 144():209-225. PubMed ID: 28947119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of the Music Therapy Assessment Tool for Advanced Huntington's Disease: A Pilot Validation Study.
    O'Kelly J; Bodak R
    J Music Ther; 2016; 53(3):232-56. PubMed ID: 27358245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Determinants of Dual Tasking in People With Premanifest Huntington Disease.
    Reyes A; Bartlett DM; Rankin TJ; Zaenker P; Turner K; Teo WP; Fu SC; Domingos J; Georgiou-Karistianis N; Ziman M; Cruickshank TM
    Phys Ther; 2021 Apr; 101(4):. PubMed ID: 33482001
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.